research SIDE EFFECTS OF CYCLOSPORINE COMPARED TO TACROLIMUS AMONG YEMENI KIDNEY TRANSPLANT PATIENTS WHO SHARE THE SAME ADJUVANT AGENTS: MYCOPHENOLATE MOFETIL AND PREDNISONE
Tacrolimus is a better option than cyclosporine due to fewer side effects.
Search
for
Sort by
Research
390-420 / 1000+ resultsresearch Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature
Tofacitinib helped psoriasis but not alopecia universalis, needing more research.
research Formulation and optimization of folate-bovine serum albumin-coated ethoniosomes of pterostilbene as a targeted drug delivery system for lung cancer: In vitro and in vivo demonstrations
The new drug delivery system effectively targets lung cancer cells.
research Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta‐analysis
Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.
research JAK Inhibitor Therapy in Alopecia Areata with Latent Hepatitis B Virus or Tuberculosis Infection: A Safety Assessment
JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.
research Risk of valproic acid-related alopecia: A systematic review and meta-analysis
Valproic acid increases the risk of hair loss more than other drugs, especially in migraine patients, and lamotrigine may be a safer alternative.
research Efficacy and Safety of SER120 Nasal Spray in Patients with Nocturia: Pooled Analysis of 2 Randomized, Double-Blind, Placebo Controlled, Phase 3 Trials
SER120 nasal spray effectively reduces nighttime urination and is safe for patients.
research Tacrolimus in Dermatology
Tacrolimus is effective for various skin conditions with fewer side effects than cyclosporine.
research Peripheral neuropathy associated with tofacitinib use in alopecia universalis
A patient developed nerve problems as a side effect of a hair loss treatment called tofacitinib.
research Two cases in which tofacitinib effectively treated both ulcerative colitis and alopecia areata
Tofacitinib effectively treated both ulcerative colitis and alopecia areata in two patients.
research Adverse events of dual anti-seizure medication: Real-life data from a tertiary epilepsy clinic
Dual anti-seizure medications, especially valproic acid with lamotrigine, often cause more side effects like hair loss and memory issues.
research 420 Alopecia in children and adults with cystic fibrosis on elexacaftortezacaftor-ivacaftor
research Successful Management of Dermatophytosis in a Desi Short Hair Domestic Kitten
The kitten's skin infection was cured with medication in three weeks.
research Treatment of resistant alopecia areata with tofacitinib
Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.
research Sacituzumab tirumotecan (sac-TMT/MK-2870/SKB264): a novel antibody–drug conjugate in breast cancer
Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
research Oral tofacitinib monotherapy in Korean patients with refractory moderate-to-severe alopecia areata: A case series
Tofacitinib is effective and safe for treating severe hair loss in Korean patients.
research Betulinic acid exerts anti‐hepatitis C virus activity via the suppression of NF ‐κB‐ and MAPK ‐ERK 1/2‐mediated COX ‐2 expression
Betulinic acid can help treat hepatitis C by stopping virus replication.
research Development of Provesicular Nanodelivery System of Curcumin as a Safe and Effective Antiviral Agent: Statistical Optimization, In Vitro Characterization, and Antiviral Effectiveness
A new delivery system makes Curcumin more effective and safer against viruses.
research An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: A case report and a review of the literature
A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.
research Madarosis and facial keratinaceous spines
Reducing immunosuppression and using antiviral creams improved the woman's skin condition.
research Clin-Alert
In 2002, various drugs caused serious side effects, including vitamin B12 deficiency, heart issues, blindness, hypersexuality, allergic reactions, blood clotting problems, pupil dilation, capillary leak syndrome, muscle breakdown, hepatitis, skin reactions, and lupus.
research Intralesional Pentoxifylline Injection Versus Triamcinolone Acetonide in Treating localized Alopecia Areata: A Comparative Study.
Pentoxifylline is a safe and effective alternative to triamcinolone acetonide for treating localized alopecia areata.
research Topical tofacitinib for the treatment of alopecia areata affecting facial hair
Topical tofacitinib may effectively and safely regrow facial hair in some people with alopecia areata.
research Formulation and Evaluation of Valproic Acid Microemulsions for Enhanced Transfollicular Delivery in Guinea Pig Skin
Valproic acid microemulsions improve skin delivery compared to regular solutions.
research Special Focus Issue: Transdermal, Topical and Folicular Drug Delivery Systems
New drug delivery systems improve treatment effectiveness and patient experience.
research Fast-Embeddable Grooved Microneedles by Shear Actuation for Accurate Transdermal Drug Delivery
New microneedles deliver drugs through the skin accurately and effectively.
research Topical sodium valproate-loaded nanospanlastics versus conventional topical steroid therapy in alopecia areata: a randomized controlled study
Both treatments for alopecia areata showed similar modest effectiveness.
research Sequential Immunotherapy with Tofacitinib and Low-Dose IL-2 Induces Sustained Remission in Alopecia Areata: A Proof-of-concept monocentric study
Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.
research Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
![Discovery of 7-Methoxy-6-[4-(4-Methyl-1,3-Thiazol-2-yl)-1H-Imidazol-5-yl]-1,3-Benzothiazole (TASP0382088): A Potent and Selective Transforming Growth Factor-β Type I Receptor Inhibitor as a Topical Drug for Alopecia](/images/research/9620bd26-3366-4f2a-bcac-f511697bbc41/small/35997.jpg)
research Discovery of 7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1<i>H</i>-imidazol-5-yl]-1,3-benzothiazole (TASP0382088): A Potent and Selective Transforming Growth Factor-β Type I Receptor Inhibitor as a Topical Drug for Alopecia
A new compound shows promise as a topical treatment for hair loss.